Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Report 2026

Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Overview

• Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices market size has reached to $0.62 billion in 2025 • Expected to grow to $1.5 billion in 2030 at a compound annual growth rate (CAGR) of 19.5% • Growth Driver: The Increasing Adoption Of Precision Medicine Approaches Is Driving The Market Due To Enhanced Data-Driven Personalized Diagnostics • Market Trend: Advancing Imaging Accuracy Through Intelligent Automated Quality Assessment Systems • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market?

Artificial intelligence-powered diagnostic radiogenomics devices are advanced medical systems that integrate imaging data with genomic and molecular profiles using artificial intelligence algorithms to identify correlations between radiographic features and underlying genetic expressions, enabling more precise disease characterization, risk stratification, and prediction of therapeutic responses at an individual patient level. These devices are utilized in clinical and research settings to enhance early detection, support personalized treatment planning, improve prognostic assessments, and facilitate the development of precision medicine approaches by bridging radiology and genomics data analytics. The main components of artificial intelligence (AI)-powered diagnostic radiogenomics devices include hardware, software, and services. Hardware refers to the physical imaging and computational systems used to capture and process medical imaging data for radiogenomic analysis. They are used with imaging modalities such as magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound, X-ray or mammography, and multi-modal fusion. The various applications involved are oncology, neurology, cardiology, and infectious diseases, and they utilize end users such as hospitals and clinics, diagnostic imaging centers, academic and research institutes and biobanks, pharmaceutical and biotechnology companies and contract research organizations, and government and public health programs.

What Is The Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Growth Forecast?

The artificial intelligence (AI)-powered diagnostic radiogenomics devices market size is expected to see rapid growth in the next few years.It will grow to $1.5 billion by 2030 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to increasing demand for AI-enabled personalized treatment planning solutions, rising adoption of cloud-based radiogenomic data analytics platforms, growing integration of genomics with diagnostic imaging workflows, increasing investment in oncology and neurology precision diagnostics, rising focus on early disease detection and predictive healthcare technologies.Major trends in the forecast period include increasing adoption of multimodal imaging and genomics integration platforms, growing demand for personalized and precision diagnostic solutions, rising use of predictive analytics for disease prognosis and therapy response assessment, increasing implementation of automated radiogenomic data interpretation tools, growing focus on real-time clinical decision support in diagnostic workflows.

Global Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Segmentation

1) By Component: Hardware, Software, Services 2) By Imaging Modality: Magnetic Resonance Imaging, Computed Tomography, Positron Emission Tomography, Ultrasound, X-Ray Or Mammography, Multi-Modal Fusion 3) By Application: Oncology, Neurology, Cardiology, Infectious Diseases 4) By End User: Hospitals And Clinics, Diagnostic Imaging Centers, Academic And Research Institutes And Biobanks, Pharmaceutical And Biotechnology Companies And Contract Research Organizations, Government And Public Health Programs Subsegments: 1) By Hardware: Imaging Sensors, Computational Processing Units, Data Storage Systems, Networking And Connectivity Modules, User Interface Devices 2) By Software: Radiogenomic Analysis Software, Artificial Intelligence Diagnostic Algorithms, Image Processing And Enhancement Software, Data Visualization And Reporting Tools, Machine Learning Model Management Software 3) By Services: Installation And Setup Services, Calibration And Maintenance Services, Training And Support Services, Data Management And Integration Services, Clinical Workflow Optimization Services

What Is The Driver Of The Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market?

The increasing adoption of precision medicine approaches is expected to propel the growth of the AI-powered diagnostic radiogenomics devices market going forward.Precision medicine approaches refer to medical strategies that tailor disease prevention, diagnosis, and treatment based on individual genetic, environmental, and lifestyle differences.The rise in precision medicine adoption is driven mainly by increasing integration of genomic data into clinical decision-making in developed healthcare systems.AI-powered diagnostic radiogenomics devices support this trend by combining medical imaging with genomic data to enable accurate disease profiling, early diagnosis, and personalized treatment planning.For instance, in February 2024, according to a report by the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, more than one-third of new drug approvals by the U.S.Food and Drug Administration were personalized therapies for four consecutive years through 2023.Therefore, the increasing adoption of precision medicine approaches is driving the growth of the AI-powered diagnostic radiogenomics devices market.

Key Players In The Global Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market

Major companies operating in the artificial intelligence (ai)-powered diagnostic radiogenomics devices market are Thermo Fisher Scientific Inc., Siemens Healthineers AG, Philips Healthcare (Koninklijke Philips N. V. ), GE HealthCare Technologies Inc., Agilent Technologies Inc., Canon Medical Systems Corporation, Tempus AI Inc., Aidoc Medical Ltd., Owkin Inc., SOPHiA GENETICS SA, Lunit Inc., Synaptive Medical Inc., Median Technologies SA, Perspectum Ltd., Quibim S. L., Seno Medical Instruments Inc., Ultromics Limited, QMENTA Inc., Imbio LLC, Mirada Medical Limited, VUNO Inc., Radiomics. bio Inc., Qlucore AB, CureMetrix Inc.

Global Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Trends and Insights

Major companies operating in the AI-powered diagnostic radiogenomics devices market are increasingly focusing on technological advancements such as imaging quality assessment tools to enhance diagnostic accuracy and standardization. An imaging quality assessment tool is a software-based system that uses advanced algorithms to evaluate, standardize, and ensure the reliability of medical imaging data. For instance, in June 2025, Quibim, a Spain-based medical imaging technology company, launched AI-QUAL, a solution that applies artificial intelligence to automatically assess prostate magnetic resonance imaging quality, assign standardized scores, and detect artifacts that may compromise diagnostic outcomes. The tool enhances radiology workflows and supports more reliable clinical decision-making by ensuring high-quality imaging data, which is essential for downstream applications such as radiogenomics.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market?

In March 2026, RadNet, a US-based outpatient diagnostic‑imaging company acquired Gleamer for $270 million. Through this acquisition, RadNet aims to expand its AI-powered radiology capabilities across X-ray, mammography, CT, and MRI imaging by integrating Gleamer’s diagnostic solutions and global SaaS platform, enhancing screening, detection, and interpretation workflows for cancer, musculoskeletal, and neurodegenerative diseases. Gleamer is a France-based company specializing in artificial intelligence-driven radiology imaging software.

Regional Insights

North America was the largest region in the artificial intelligence (AI)-powered diagnostic radiogenomics devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market?

The artificial intelligence (AI)-powered diagnostic radiogenomics devices market consists of sales of radiogenomic data integration platforms, artificial intelligence-based image–genomic correlation software, predictive analytics engines for genotype–phenotype mapping, cloud-enabled radiogenomics processing systems,, genomic annotation and imaging biomarker extraction tools, and interoperable radiology–genomics data management systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Industry?

The artificial intelligence (ai)-powered diagnostic radiogenomics devices market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (ai)-powered diagnostic radiogenomics devices industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Report 2026?

The artificial intelligence (AI)-powered diagnostic radiogenomics devices market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI)-powered diagnostic radiogenomics devices market statistics, including artificial intelligence (AI)-powered diagnostic radiogenomics devices industry global market size, regional shares, competitors with a artificial intelligence (AI)-powered diagnostic radiogenomics devices market share, detailed artificial intelligence (AI)-powered diagnostic radiogenomics devices market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-powered diagnostic radiogenomics devices industry. This artificial intelligence (AI)-powered diagnostic radiogenomics devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.